Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

ClinicalTrials.gov ID: NCT01712516

Public ClinicalTrials.gov record NCT01712516. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will assess the efficacy, safety and tolerability of indacaterol maleate/glycopyrronium bromide in patients with moderate to severe airflow limitation.

Study identification

NCT ID
NCT01712516
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
1,001 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2012 (Type not available)
Primary completion
Feb 2014 (Actual)
Completion
Feb 2014 (Actual)
Last update posted
Jul 15, 2015

2012 – 2014

United States locations

U.S. sites
56
U.S. states
12
U.S. cities
49
Facility City State ZIP Site status
Novartis Investigative Site Huntsville Alabama 35801 —
Novartis Investigative Site *See Various Dept.'s* Arizona — —
Novartis Investigative Site Tempe Arizona 85283 —
Novartis Investigative Site Buena Park California 90620 —
Novartis Investigative Site Fullerton California 92835 —
Novartis Investigative Site Palmdale California 93551 —
Novartis Investigative Site Riverside California 92506 —
Novartis Investigative Site San Diego California 92120 —
Novartis Investigative Site Sepulveda California 91343 —
Novartis Investigative Site Clearwater Florida 33756 —
Novartis Investigative Site Clearwater Florida 33765 —
Novartis Investigative Site DeLand Florida 32720 —
Novartis Investigative Site Fort Lauderdale Florida 33316-192 —
Novartis Investigative Site Miami Florida 33156 —
Novartis Investigative Site Miami Florida 33186 —
Novartis Investigative Site Orlando Florida 32806 —
Novartis Investigative Site Pensacola Florida 32503 —
Novartis Investigative Site Pensacola Florida 32504 —
Novartis Investigative Site Port Orange Florida 32127 —
Novartis Investigative Site Sarasota Florida 34233 —
Novartis Investigative Site Tamarac Florida 33321 —
Novartis Investigative Site Tampa Florida 33603 —
Novartis Investigative Site Winter Park Florida 32789 —
Novartis Investigative Site Lawrenceville Georgia 30046 —
Novartis Investigative Site Opelousas Louisiana 70570 —
Novartis Investigative Site Henderson Nevada 89014 —
Novartis Investigative Site Las Vegas Nevada 89119 —
Novartis Investigative Site Reno Nevada 89520 —
Novartis Investigative Site Brandon New Jersey 33511 —
Novartis Investigative Site Charlotte North Carolina 28207 —
Novartis Investigative Site Huntersville North Carolina 28078 —
Novartis Investigative Site Raleigh North Carolina 27607 —
Novartis Investigative Site Shelby North Carolina 28150 —
Novartis Investigative Site Shelby North Carolina 28152 —
Novartis Investigative Site Charleston South Carolina 29406-7108 —
Novartis Investigative Site Charleston South Carolina 29412 —
Novartis Investigative Site Columbia South Carolina 29201 —
Novartis Investigative Site Easley South Carolina 29640 —
Novartis Investigative Site Gaffney South Carolina 29340 —
Novartis Investigative Site Greenville South Carolina 29615 —
Novartis Investigative Site Pelzer South Carolina 29669 —
Novartis Investigative Site Rock Hll South Carolina 29732 —
Novartis Investigative Site Seneca South Carolina 29678 —
Novartis Investigative Site Simpsonville South Carolina 29681 —
Novartis Investigative Site Spartanburg South Carolina 29303 —
Novartis Investigative Site Union South Carolina 29379 —
Novartis Investigative Site Johnson City Tennessee 37601 —
Novartis Investigative Site Arlington Texas 76012 —
Novartis Investigative Site Corsicana Texas 75110 —
Novartis Investigative Site Dallas Texas 75216 —
Novartis Investigative Site Dallas Texas 75235 —
Novartis Investigative Site Fort Worth Texas 76104 —
Novartis Investigative Site Fort Worth Texas 76107 —
Novartis Investigative Site Lufkin Texas 75904 —
Novartis Investigative Site McKinney Texas 75069 —
Novartis Investigative Site Tyler Texas 75708 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01712516, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 15, 2015 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01712516 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →